
Afayro 30 Tablet
Marketer
Glenmark Pharmaceuticals Ltd
Salt Composition
Afatinib dimaleate (30mg)
Overview Afayro 30 Tablet
Erlotinib 30mg tablets are indicated for treating non-small cell lung cancer in adults with specific epidermal growth factor receptor (EGFR) gene mutations. Optimal absorption requires administration on an empty stomach, consistently at the same time daily for maximum efficacy. Dosage and frequency are determined by your physician based on your individual needs and may vary. Strict adherence to your doctor's prescribed regimen is crucial; improper use or overdose can lead to severe adverse events. Therapeutic benefits may not be apparent for weeks or months; discontinue use only as directed by your doctor. Common side effects include nausea, diarrhea, rash, and dry skin. Severe diarrhea requires prompt medical attention and management, including hydration. Regular blood monitoring may be recommended. Photosensitivity is a potential side effect, necessitating sun protection. Report any ocular discomfort, such as dryness, redness, or pain. Prior to commencing treatment, disclose any pre-existing respiratory, hepatic, or renal conditions, and all current medications, particularly those used for infections, to your physician. Significant drug interactions are possible; ensure comprehensive disclosure of all medications to your healthcare provider. This medication is contraindicated during pregnancy and breastfeeding; effective contraception is essential for female patients undergoing treatment.
Uses of Afayro 30 Tablet
Lung cancer (excluding small cell types)
Major Benefits of Afayro 30 Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer Afayro 30 Tablet on an empty stomach.
Common Side effects of Afayro 30 Tablet:
- Diarrhea
- Rash
- Dry skin
- Nausea
- Vomiting
- Loss of appetite
- Itching
- Stomatitis (Inflammation of the mouth)
- Nail disorder
How to use Afayro 30 Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Afayro 30 Tablet should be taken on an empty stomach.
How Afayro 30 Tablet works:
Afayro 30 Tablet is an anticancer drug that targets and blocks specific enzyme receptors (EGFR, HER2, and HER4) crucial for cancer cell proliferation. This inhibition disrupts vital signaling pathways, effectively slowing or halting cancer progression.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse interactions between Afayro 30 Tablet and alcohol consumption.
PregnancyCONSULT YOUR DOCTOR
Use of Afayro 30 Tablet during pregnancy is contraindicated due to established risks to the fetus. In exceptional life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Physician consultation is advised.
Breast feedingCONSULT YOUR DOCTOR
The use of Afayro 30 Tablet while breastfeeding is likely inadvisable. Scant human evidence indicates potential transfer to breast milk, posing a possible risk to the infant.
DrivingCONSULT YOUR DOCTOR
Afayro 30 Tablet's effect on driving ability is unknown. Refrain from driving if you experience symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
Afayro 30 Tablet appears to be safe for individuals with kidney impairment. Existing evidence indicates dose modification may not be necessary, but physician consultation is recommended.
LiverSAFE IF PRESCRIBED
Afayro 30 Tablet appears to pose minimal risk for individuals with hepatic impairment. Existing evidence indicates dose modification may not be necessary, however, medical advice is recommended.
What if you forget to take Afayro 30 Tablet :
Omit any missed Afayro 30 Tablet dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Afayro 30 Tablet
| Label | Value |
|---|---|
| Chemical Type | Quinazoline-Butenamide Hybrid |
| Developing Habits | No. |
| Treatment Category | Cancer Treatments |
| Behavior Class | Kinase inhibitors targeting tyrosine |
